Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis

Cornea

Volumn 30, Issue 1, 2011, Pages 83-90

  Sanders, Melissa E ^a   Moore, Quincy C ^a   Norcross, Erin W ^a   Sanfilippo, Christine M ^b   Hesje, Christine K ^b   Shafiee, Afshin ^b   Marquart, Mary E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b BAUSCH AND LOMB   (United States)

Author keywords

besifloxacin; fluoroquinolone; gatifloxacin; keratitis; moxifloxacin; Pseudomonas aeruginosa

Indexed keywords

AMINO ACID; BESIFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; PHOSPHATE BUFFERED SALINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; GENE MUTATION; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; RABBIT; SEQUENCE ANALYSIS;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZEPINES; COLONY COUNT, MICROBIAL; CORNEAL ULCER; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; FEMALE; FLUOROQUINOLONES; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLINES; RABBITS; SEQUENCE ANALYSIS, DNA;

EID: 78650951199     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181e2f0f3     Document Type: Article

References (59)

1. Erie JC, Nevitt MP, Hodge DO, et al. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol. 1993; 111:1665-1671.
2. Hsaio CH, Yeung L, Ma DH, et al. Pediatric microbial keratitis in Taiwanese children: a review of hospital cases. Arch Ophthalmol. 2007; 125:603-609.
3. Pachigolla G, Blomquist P, Cavanagh HD. Microbial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north Texas. Eye Contact Lens. 2007;33:45-49.
4. Sun X, Deng S, Li R, et al. Distribution and shifting trends of bacterial keratitis in north China (1989-98). Br J Ophthalmol. 2004;88:165-166.
5. Ahuja M. Contact lens wear and microbial keratitis. J Indian Med Assoc. 2002;100:664-666.
6. Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Ulcerative keratitis associated with contact lens wear. Indian J Ophthalmol. 2007;55:64-67.
7. Mah-Sadorra JH, Yavuz SG, Najjar DM, et al. Trends in contact lensrelated corneal ulcers. Cornea. 2005;24:51-58.
8. Preechawatmd P, Ratananikommd U, Lerdvitayasakul R, et al. Contact lens-related microbial keratitis. J Med Assoc Thai. 2007;90:737-743.
9. Yu DK, Ng AS, Lau WW, et al. Recent pattern of contact lens-related keratitis in Hong Kong. Eye Contact Lens. 2007;33:284-287.
10. Watt K, Swarbrick HA. Microbial keratitis in overnight orthokeratology: review of the first 50 cases. Eye Contact Lens. 2005;31:201-208.
11. Chen JH, Ma DH, Tsai RJ. Amniotic membrane transplantation for pseudomonal keratitis with impending perforation. Chang Gung Med J. 2002;25:144-152.
12. Ormerod LD. Causes and management of bacterial keratitis in the elderly. Can J Ophthalmol. 1989;24:112-116.
13. Ti SE, Scott JA, Janardhanan P, et al. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol. 2007;143:755-762.
14. Tsai AC, Tseng MC, Chang SW, et al. Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. J Formos Med Assoc. 1995;94:760-764.
15. Jeng BH, McLeod SD. Microbial keratitis. Br J Ophthalmol. 2003;87: 805-806.
16. Willcox MD. Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review. Optom Vis Sci. 2007;84:273-278.
17. McLeod SD, DeBacker CM, Viana MA. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology. 1996;103: 479-484.
18. Forster RK. Conrad Berens lecture: the management of infectious keratitis as we approach the 21st century. CLAO J. 1998;24:175-180.
19. Smith A, Pennefather PM, Kaye SB, et al. Fluoroquinolones: place in ocular therapy. Drugs. 2001;61:747-761.
20. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and antitopoisomerase resistance. Biochim Biophys Acta. 1998;1400:45-61.
21. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol. 1999;2:504-508.
22. Neuhauser M, Weinstein R, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885-888.
23. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis. 1998;27: S93-S99.
24. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61:377-392.
25. Poole K, Heinrichs DE, Neshat S. Cloning and sequence analysis of an EnvCD homologue in Pseudomonas aeruginosa: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. Mol Microbiol. 1993a;10:529-544.
26. Poole K, Krebes K, McNally C, et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol. 1993b;175:7363-7372.
27. Poole K, Gotoh N, Tsujimoto H, et al. Overexpression of the mexC-mexDoprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol. 1996;21:713-724.
28. Kohler T, Michea-Hamzehpour M, Henze U, et al. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol. 1997;23:345-354.
29. Li HZ, Livermore DM, Nikaido H. Role of efflux pump (s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother. 1994;38:1732-1741.
30. Thibodeaux BA, Dajcs JJ, Caballero AR, et al. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Curr Eye Res. 2004;28:337-342.
31. Mah FS, Romanowski EG, Kowalski RP, et al. Zymar (gatifloxacin 0.3%) shows excellent gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand white rabbit keratitis model. Cornea. 2007;26:585-588.
32. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology. 2001;108:1826-1829.
33. Duggirala A, Joseph J, Sharma S, et al. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol. 2007;55:15-19.
34. Moshirfar M, Mirzaian G, Feiz V, et al. Fourth-generation fluoroquinolone- resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006;32:515-518.
35. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552-3560.
36. Sanders ME, Norcross EW, Moore QC III, et al. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Cornea. 2009;28:1055-1060.
37. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Sixteenth Informational Supplement. Clinical and Laboratory Standards Institute Document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006b.
38. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Clinical and Laboratory Standards Institute Document M7-A7. 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2006a.
39. Johnson MK, Hobden JA, Hagenah M, et al. The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1990;9: 1107-1114.
40. Shelburne SA III, Keith D, Horstmann N, et al. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci U S A. 2008;105:1698-1703.
41. Wilhelmus K, Abshire R, Schlech B. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003;121:1229-1233.
42. Kaye S, Tuft S, Neal T, et al. Bacterial susceptibility to topical antimicrobial and clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51:362-368.
43. Michea-Hamzehpour M, Auckenthaler R, Regamey P, et al. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother. 1987;31:1803-1808.
44. Akasaka T, Tanaka M, Yamaguchi A, et al. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother. 2001;45:2263-2268.
45. Karlowsky JA, Draghi DC, Jones ME, et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003;47:1681-1688.
46. Jalal S, Ciofu O, Hoiby N, et al. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2000;44:710-712.
47. Lee JK, Lee YS, Park YK, et al. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2005;25:290-295.
48. Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63:443-450.
49. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43: 410-412.
50. Pestova E, Millichap JJ, Noskin GA, et al. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45:583-590.
51. Schedletzky H, Wiedemann B, Heisig P. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother. 1999;43(Suppl B):31-37.
52. Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother. 1998; 42:2678-2681.
53. Epstein SP, Bottone EJ, Asbell PA. Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infections. Eye Contact Lens. 2006;32:240-244.
54. Muramatsu H, Horii T, Takeshita A, et al. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Chemotherapy. 2005;51: 70-75.
55. Zhang J-Z,Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J Antimicrob Chemother. 2008;61:111-116.
56. Fleiszig SM, Efron N, Pier GB. Extended contact lens wear enhances Pseudomonas aeruginosa adherence to human corneal epithelium. Invest Ophthalmol Vis Sci. 1992;33;2908-2916.
57. Chang DC, Grant GB, ODonnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953-963.
58. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31:514-526.
59. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25:1159-1169.